Form 8-K - Current report:
SEC Accession No. 0001213900-24-104555
Filing Date
2024-12-02
Accepted
2024-12-02 16:10:19
Documents
16
Period of Report
2024-11-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0223210-8k_nkgen.htm   iXBRL 8-K 53477
2 CONDITIONAL INVESTMENT AGREEMENT, DATED NOVEMBER 20, 2024, BY AND BETWEEN NKGEN ea022321001ex10-1_nkgen.htm EX-10.1 209928
3 PRESS RELEASE, DATED DECEMBER 2, 2024 ea022321001ex99-1_nkgen.htm EX-99.1 18521
  Complete submission text file 0001213900-24-104555.txt   544557

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nkgn-20241125.xsd EX-101.SCH 3882
5 XBRL DEFINITION FILE nkgn-20241125_def.xml EX-101.DEF 26779
6 XBRL LABEL FILE nkgn-20241125_lab.xml EX-101.LAB 37008
7 XBRL PRESENTATION FILE nkgn-20241125_pre.xml EX-101.PRE 25403
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0223210-8k_nkgen_htm.xml XML 6009
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 241519119
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)